Nu Skin Enterprises (NYSE:NUS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.
According to Zacks, “Nu Skin has seen its shares decline and underperform the industry in the past month. The company has been struggling with declining gross margins for a while, thanks to lower margins from acquired businesses. This remains a threat. Moreover, the company remains exposed to significant currency risks stemming from international markets and stiff competition from the existence of strong peers and abundant product alternatives. Nonetheless, the company’s top line has been consistently benefitting from growth in sales leaders. During the first quarter of 2018, sales leaders improved approximately 16% and customer base increased 7%. During the quarter, revenues grew in all regional segments. To sustain such solid trends, Nu Skin remains on track with initiatives to enhance technological capabilities along with well-knit product launches and marketing programs.”
Other analysts also recently issued reports about the company. ValuEngine downgraded Nu Skin Enterprises from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 6th. Jefferies Financial Group started coverage on Nu Skin Enterprises in a research report on Thursday, June 14th. They set a “buy” rating and a $98.00 target price on the stock. Deutsche Bank downgraded Nu Skin Enterprises from a “buy” rating to a “hold” rating and set a $77.00 target price on the stock. in a research report on Friday, April 13th. Finally, Citigroup boosted their target price on Nu Skin Enterprises from $81.00 to $82.00 and gave the stock a “buy” rating in a research report on Monday, April 30th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $77.00.
Nu Skin Enterprises traded down $0.45, reaching $77.74, on Monday, MarketBeat reports. 11,341 shares of the company’s stock were exchanged, compared to its average volume of 435,740. Nu Skin Enterprises has a twelve month low of $53.50 and a twelve month high of $84.00. The firm has a market capitalization of $4.35 billion, a PE ratio of 24.04, a P/E/G ratio of 2.40 and a beta of 1.38. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.14 and a quick ratio of 0.75.
Nu Skin Enterprises (NYSE:NUS) last announced its quarterly earnings data on Thursday, April 26th. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.09. Nu Skin Enterprises had a return on equity of 25.36% and a net margin of 5.74%. The firm had revenue of $616.00 million for the quarter, compared to analyst estimates of $564.46 million. During the same quarter in the prior year, the company posted $0.51 earnings per share. Nu Skin Enterprises’s quarterly revenue was up 23.4% on a year-over-year basis. equities research analysts expect that Nu Skin Enterprises will post 3.55 earnings per share for the current fiscal year.
In other news, Director Neil H. Offen sold 7,000 shares of the company’s stock in a transaction on Thursday, June 7th. The stock was sold at an average price of $81.66, for a total value of $571,620.00. Following the sale, the director now directly owns 11,267 shares in the company, valued at $920,063.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel D Matthew Dorny sold 2,000 shares of the company’s stock in a transaction on Wednesday, April 4th. The shares were sold at an average price of $75.00, for a total value of $150,000.00. Following the completion of the sale, the general counsel now owns 47,878 shares in the company, valued at $3,590,850. The disclosure for this sale can be found here. Insiders sold 106,500 shares of company stock worth $8,025,195 over the last 90 days. Company insiders own 3.00% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in NUS. Millennium Management LLC increased its stake in Nu Skin Enterprises by 937.5% in the first quarter. Millennium Management LLC now owns 422,098 shares of the company’s stock valued at $31,113,000 after purchasing an additional 381,414 shares during the last quarter. Mackay Shields LLC acquired a new stake in Nu Skin Enterprises during the first quarter worth about $23,903,000. Renaissance Technologies LLC acquired a new stake in Nu Skin Enterprises during the fourth quarter worth about $13,373,000. UBS Asset Management Americas Inc. increased its stake in Nu Skin Enterprises by 381.4% during the fourth quarter. UBS Asset Management Americas Inc. now owns 224,985 shares of the company’s stock worth $15,351,000 after acquiring an additional 178,250 shares during the last quarter. Finally, OppenheimerFunds Inc. grew its stake in shares of Nu Skin Enterprises by 1,497.3% in the first quarter. OppenheimerFunds Inc. now owns 148,041 shares of the company’s stock valued at $10,912,000 after buying an additional 138,773 shares in the last quarter. Hedge funds and other institutional investors own 76.20% of the company’s stock.
About Nu Skin Enterprises
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.